IDiyas

For the Inventor, By the Inventor

Old Lyme, CT, United States of America

Matthew Scott Dowling

LinkedIn
USPTO Granted Patents = 18 

 

 

Average Co-Inventor Count = 11.9

ph-index = 5

Forward Citations = 70(Granted Patents)


Location History:

  • Groton, CT (US) (2014 - 2016)
  • Old Lyme, CT (US) (2017 - 2024)

Company Filing History:

goldMedal18 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):
1. 12319669 - GLP-1 receptor agonists and uses thereof (2025-06-03),
2. 11866425 - Diacylglycerol acyl transferase 2 inhibitors (2024-01-09),
3. 11802121 - GLP-1 receptor agonists and uses thereof (2023-10-31),
4. 11634410 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2023-04-25),
5. 11512070 - GLP-1 receptor agonists and uses thereof (2022-11-29),
6. 11034678 - Diacylglycerol acyl transferase 2 inhibitors (2021-06-15),
7. 10988463 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2021-04-27),
8. 10851081 - GLP-1 receptor agonists and uses thereof (2020-12-01),
9. 10787438 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2020-09-29),
10. 10669259 - GLP-1 receptor agonists and uses thereof (2020-06-02),
11. 10208019 - GLP-1 receptor agonists and uses thereof (2019-02-19),
12. 10174007 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2019-01-08),
13. 10071992 - Diacylglycerol acyl transferase 2 inhibitors (2018-09-11),
14. 9873673 - 2-thiopyrimidinones (2018-01-23),
15. 9809579 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2017-11-07),

Title: Innovator Spotlight: Matthew Scott Dowling

Introduction

Matthew Scott Dowling is a notable inventor based in Old Lyme, Connecticut, with an impressive portfolio of 17 patents. His work primarily focuses on cutting-edge pharmaceutical compounds that hold the potential to significantly impact the treatment of various diseases.

Latest Patents

Among his latest patents are innovative compounds that inhibit the activity of diacylglycerol acyltransferase 2 (DGAT2). These compounds, known as Formula I, are being explored for their uses in the treatment of diseases linked to this enzyme in animals. Additionally, he has developed GLP-1 receptor agonists, which are 6-carboxylic acids of benzimidazoles and their derivatives. These compounds not only offer therapeutic potential but also encompass processes for their synthesis and methods of administration for mammals in need.

Career Highlights

Matthew currently contributes his extensive expertise at Pfizer Corporation, a leading global biopharmaceutical company. In his role, he has made significant strides in advancing research and development within the pharmaceutical field, further cementing his status as an influential figure in innovation.

Collaborations

Throughout his career, Matthew has collaborated with esteemed colleagues, including Kentaro Futatsugi and Kim Huard. These partnerships foster dynamic exchanges of ideas and knowledge that contribute to the successful development of novel pharmaceutical solutions.

Conclusion

Matthew Scott Dowling exemplifies dedication and ingenuity in the realm of inventions and innovations. His contributions to the pharmaceutical industry not only reflect his talents as an inventor but also signify the potential impact of his work in improving the health and well-being of populations worldwide. As he continues to innovate, his future endeavors are keenly anticipated within the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…